Drug delivery device for intradermal injection

VAX-IDTM is a patented and award-winning easy to use platform of non-prefilled and prefilled devices suited for accurate injection and drug delivery in the dermis, the skin layer underneath the epidermis or upper layer of the skin. Intradermal injection allows for an improved immune response. The unique injection system allows for painless injection. VAX-IDTM  can be used for both prophylactic and therapeutic intradermal vaccination as well as for anti-allergic drugs and other substances suited for injection in the skin. The VAX-IDTM platform is currently in development stage and allow for injection of different volumes, use of different needle thicknesses and length depending on the application. CE marking is expected Spring 2017.

Awards: 'Best of PO' in 2012, 'BiR&D Award' in 2012 & 'Belgian James Dyson Award' in 2014

Intradermal injection

VAX-ID non-prefilled intradermal injection and drug delivery device

VAX-IDTM is a suited for accurate intradermal injection and drug delivery. The skin consists of three layers: the outer layer or epidermis, the dermis, and the hypodermis or subcutaneous fat layer. The VAX-IDTM platform is under development to allow use of different needle thicknesses (26G - 34G) and lengths for delivery of small volumes (0.05cc - 0.2cc per injection). The short and thin, almost invisible needle is considered an advantage for people with needle phobia and make people feel more at ease during the injection. Compared to the Mantoux technique which requires a high amount of training and difficult to standardize as it uses a regular needle and syringe to be inserted at an angle of 10 to 15°, VAX-IDTM allows for a standardized and accurate injection and drug delivery perpendicular to the skin.


Prophylactic vaccination

VAX-ID non-prefilled intradermal injection and drug delivery device and syringe

VAX-IDTM can be used for prophylactic intradermal vaccination. Prophylactic vaccines are used to prevent diseases: examples include vaccination against polio, rabies, human papilloma virus (HPV), influenza (flu), and hepatitis B. The dermis is an attractive site for injection and especially vaccination as the dermis is highly vascularized and contains numerous immune cells, including a high number of dendritic cells. Intradermal vaccination has three big advantages over intramuscular or subcutaneous vaccination: (1) an improved immune response to vaccine antigens; (2) potential reduction of antigen-dose, and (3) decreased anxiety and pain. Especially in elderly people improved immune responses have been described after intradermal flu vaccination.

Therapeutic vaccination

VAX-ID non-prefilled intradermal injection and drug delivery device ready for use

VAX-IDTM allows therapeutic vaccination, vaccineswhich are used to treat diseases rather than prevent them. Examples include vaccines against cancer, infectious diseases, and auto-immune diseases. Therapeutic vaccines are typically administered at the site of indication: the therapeutic cervical cancer vaccine, for instance, is administered in the groin. VAX-IDTM allows for a standardized and accurate injection at the site of infection and at various anatomic sites. Its unique design and possibility to use different short and thin needles to allow for injection of various vaccines.

Product specifications

Exploded view VAX-ID prefilled
  • Accurate injection & drug delivery in the dermis
  • Painless injection
  • User-independent
  • Easy to use
  • De-risk clinical trials
  • Activation protection
  • Safety locking
  • Prevents needle-stick injuries
  • Prevents re-use
  • Improved immune response
  • Dose-sparing potential
Clinical studies: 
BiR&D study (Belgium)

Aim: Assessment of and acceptability and usability of a new prototype device for intradermal injection, VAX-IDTM

  • 102 healthy volunteers aged 18 to 65
  • Comparison of injection site (upper arm and lower arm), route of administration (ID and IM)
  • Assessment of usability by study nurses

Conclusion: The new prototype device, VAX-IDTM, was found easy to handle, easy to use and safe 

Publication: Van Mulder T et al. Human Vaccines and Immunotherapeutics 2014

Hepatitis B Proof of Concept study (Belgium)

Aim: Assessment of immunogenicity and safety of intradermal injection of HBV using VAX-IDTM

  • 30 healthy volunteers aged 18 to 64
  • Inclusion criterium: baseline value HBV titers known
  • Comparison route of administration (ID and IM) and ID administration (Mantoux technique and VAX-IDTM

Conclusion: Data analysis ongoing

Device materialMedical grade polypropylene & polycarbonate
Needle thickness26G-36G
Needle length0.8-1.2 mm injection depth (customization possible)
Volume0.05cc - 0.2cc per injection
Anatomic sites for injectionMultiple

Novosanis NV | +32 3 485 50 16 | welcome@novosanis.comBijkhoevelaan 32c, 2110 Wijnegem | Belgium